



Mantle cell lymphoma is a clinicopathologic entity that
is now recognized as a distinct subtype of non-Hodgkin’s
lymphoma (NHL). This entity has been previously called
diffuse poorly differentiated lymphocytic lymphoma, dif-
fuse small cleaved-cell lymphoma, intermediate lympho-
cytic lymphoma, and mantle-zone lymphoma [1-4]. Based
on uniform histologic, immunophenotypic, and genotypic
features, hematopathologists now diagnose mantle cell
lymphoma in approximately 6% to 9% of NHL cases [5-7].
Patients with mantle cell lymphoma typically present with
advanced-stage disease which frequently includes bone
marrow, blood, and splenic involvement [8]. Although
mantle cell lymphoma was previously thought to represent
a form of indolent lymphoma, it has more recently been
recognized that the median survival of patients with this
type of lymphoma is only 3 years versus 7 to 9 years with
typical “indolent” NHL [8,9].
Unlike other aggressive NHLs, however, patients with
mantle cell lymphoma have a poorer complete response rate
with standard anthracycline-based or non–anthracycline-
based chemotherapy [10,11]. Progression of this lymphoma
typically occurs within the ﬁrst 12 to 18 months after the ini-
tial diagnosis despite conventional chemotherapy [12]. Stan-
dard salvage regimens have not appeared to have much suc-
cess in producing second long-term remissions in this disease
[13]. Because high-dose chemotherapy (HDC) and autolo-
gous transplantation have been superior to conventional sal-
vage therapy in other types of aggressive NHL, this treatment
has now been applied to patients with mantle cell lymphoma
who were otherwise transplantation candidates.
This study evaluates the results of HDC and autolo-
gous hematopoietic stem cell transplantation (autoHSCT) in
patients with mantle cell lymphoma referred to the University of
Nebraska Medical Center (Omaha, NE) at various points in
their disease course.
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ABSTRACT
This study evaluated the outcomes of patients who underwent high-dose chemotherapy (HDC) and autologous hemato-
poietic stem cell transplantation (autoHSCT) for mantle cell non-Hodgkin’s lymphoma and the effect of clinical and treat-
ment characteristics. The clinical outcome and prognostic factors in 40 patients who underwent HDC and autoHSCT for
mantle cell lymphoma between June 1991 and August 1998 were analyzed. With a median follow-up of 24 months for the
surviving patients (range, 4-68 months), the 2-year overall survival was 65% and the 2-year event-free survival (EFS) was
36%. In univariate analysis, characteristics predictive of a poor EFS were blastic morphology (P = .019) and the patient hav-
ing received 3 or more prior chemotherapy regimens (P = .004). In a multivariate analysis, the only factor associated with a
poor EFS was the number of prior chemotherapy regimens. Those patients who received 3 or more prior therapies had a
2-year EFS of 0%, and those who received <3 therapies had a 2-year EFS of 45% (P = .004). Patients with mantle cell lym-
phoma can obtain prolonged EFS with HDC and autoHSCT; however, this strategy for prolonged EFS appears to work
optimally in patients who are less heavily pretreated. Whether this therapy will increase the overall survival or EFS in
patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials.
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PATIENTS AND METHODS
Between June 1991 and August 1998, 40 patients with
mantle cell lymphoma were treated with HDC and autoHSCT
at the University of Nebraska Medical Center. Patients
included in this study had lymph node biopsies reviewed and
classified according to the Revised European American
Lymphoma (REAL) classiﬁcation by 1 of 3 hematopatholo-
gists (D.D.W., W.C.C., T.C.G.) [14]. Bone marrow, blood
smears, and other pathologic specimens were also reviewed
as appropriate for the patient’s clinical circumstance.
Patients were eligible for transplantation before 1996 if
they had failed to achieve an initial remission or had
relapsed after attaining a remission with conventional ther-
apy. Starting in 1996, patients in first complete remission
were also offered transplantation. Transplantation protocols
were approved by the Institutional Review Board (IRB), and
informed consent was obtained from all patients before
transplantation. Entry criteria required a cardiac ejection
fraction ≥50% and a carbon monoxide diffusion capacity
≥50% of predicted normal value. Normal hepatic and renal
function were required unless dysfunction could be attrib-
uted to the presence of lymphoma. During the latter period
of patient accrual, a negative human immunodeﬁciency virus
antibody test result was required before transplantation.
During the early period of patient accrual, patients
received transplants of autologous unpurged bone marrow.
A bone marrow biopsy within 1 month of harvest was
required to be morphologically free of lymphoma, although
patients may have had previous bone marrow involvement.
During the latter period of patient accrual, patients received
transplants of mobilized autologous peripheral blood pro-
genitors. The upper age limit for transplantation was
60 years until March 1992, when the limit was removed as
long as the patient met other physiological entry criteria.
Those patients receiving autologous bone marrow were
given general anesthesia while it was harvested. Marrow
was collected for a minimum nucleated cell count of 2.0 
108/kg and frozen at a controlled rate and preserved in 10%
dimethylsulfoxide (DMSO). In those patients receiving
peripheral blood progenitors, the cells were collected using
cytokine mobilization with granulocyte-macrophage
colony-stimulating factor (GM-CSF), G-CSF, erythropoi-
etin, or PIXY-321, depending on the mobilization trial in
effect at the time. No chemotherapy mobilization was used.
Peripheral blood progenitor cells were preserved in 10%
DMSO and frozen at a controlled rate or, more recently,
preserved in 5% DMSO and 6% hydroxyethyl starch,
frozen at –130°C, and stored in liquid nitrogen.
At the time of their enrollment, patients were treated
with IRB-approved regimens based on histology and
chemotherapy sensitivity; these regimens were either total
body irradiation (TBI)-based (n = 6, 15%) or chemotherapy
only (n = 34, 85%). Patients in the TBI-based group
received cyclophosphamide, 60 mg/kg  2 days, and
200 cGy TBI BID  3 days (Cy/TBI) (n = 6). The patients
in the chemotherapy-only groups received ifosfamide, 3 g/m2
per day  4, carboplatin, 1.2 g/m2 over 96 hours by contin-
uous infusion, and etoposide, 400 mg/m2 per day  3 (ICE)
(n = 1); carmustine, 300 mg/m2, etoposide, 100 mg/m2 bid
 4, cytarabine, 100 mg/m2 bid  4, and cyclophos-
phamide, 35 mg/kg  4 (BEAC) (n = 25); BEAC with 131I
anti-CD20 (n = 3); 300 mg/m2 carmustine, 100 mg/m2
etoposide, 100 mg/m2 cytarabine, and 140 mg/m2 melphalan
(BEAM) (n = 2); and BEAM with rituximab (n = 2). Because
no outcome differences were noted with the different proto-
cols, the TBI-based and the chemotherapy-only regimens
were grouped together for the purposes of this study.
Patients were treated in private rooms with high-effi-
ciency particulate air ﬁltration. During the study, GM-CSF,
G-CSF, or PIXY-321 was administered posttransplantation
depending on the protocol in effect at the time. Irradiated
platelet transfusions were given to keep the platelet count
≥20,000/µL, and irradiated packed red blood cell transfu-
sions were given to maintain hemoglobin levels >8 g/dL.
Response Evaluation
Staging evaluations were performed before transplanta-
tion, approximately 100 days after transplantation, and then
at yearly intervals. A complete response (CR) was deﬁned as
disappearance of all clinical and radiographic evidence of
disease (lymph nodes <1.5 cm) at the day-100 evaluation.
Patients with small residual radiographic abnormalities who
did not progress between the day-100 evaluation and at a
subsequent evaluation at least 3 months after the day-100
evaluation were considered to have a CR-unconfirmed
(CR-u). A partial response (PR) was defined as a ≥50%
reduction in the surface area of measurable disease at the
day-100 evaluation. All other patients were classiﬁed as hav-
ing had no response to transplantation. Bone marrow was
evaluated with histologic methods, and molecular method-
ology was not used in the determination of response.
Statistical Methods
The association between patient and transplant charac-
teristics and histology was examined using the chi-square
test for association. Transplantation outcome was analyzed
with respect to overall survival and event-free survival.
Overall survival time was defined as the time from trans-
plantation until death from any cause or until last follow-
up, for surviving patients. EFS was deﬁned as the time from
transplantation until relapse from CR, disease progression,
death from any cause, or last follow-up if none of those
events had occurred. Survival times and EFS distributions
were calculated using the product-limit Kaplan-Meier
method [15]. Comparisons of these time-to-event distribu-
tions were made using the log-rank test [16]. Multivariate
analysis was performed using the Cox proportional hazards
regression model [17].
RESULTS
The 40 patients ranged in age from 34 to 67 years
(median, 56 years), and 78% of the patients were men. Other
characteristics of patient are noted in Table 1. Of the patients,
26 (65%) had diffuse mantle cell lymphoma, 5 (13%) had
nodular or mantle zone lymphoma, and 9 (23%) had blastic
mantle cell lymphoma. Bone marrow involvement was pres-
ent at the time of transplantation in 26 (67%) of the
patients. An elevated serum lactate dehydrogenase (LDH)
level was present at the time of transplantation in 14 (35%)
of the patients. A total of 70% of patients had never been
in a complete remission before transplantation (primary
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induction failure). However, 93% of the patients remained
chemotherapy sensitive at the time of transplantation. The
median time from diagnosis to transplantation was
11 months (range, 3-40 months).
None of the 40 patients died early during the transplan-
tation. The median time to reach an absolute neutrophil
count of >500/µL was 12 days (range, 8-38 days). The
median time to platelet transfusion independence was also
12 days (range, 7-154 days). Red blood cell transfusion inde-
pendence was attained at a median of 10 days (range, 4-98
days). The response to transplantation was a CR in 14
patients (35%), CR-u in 9 (23%), and PR in 11 (28%). The
overall response rate was 86%.
With a median follow-up of 24 months (range,
4-68 months) for the surviving patients, the 2-year EFS for
all patients was 35% (Figure 1) and the 2-year overall sur-
vival was 65% (Figure 2) with no obvious plateau on the
curves. The majority of deaths (11 of 13) were due to lym-
phoma progression or recurrence; however, 1 patient died
of acute graft-versus-host disease after a second allogeneic
transplantation and another patient died of renal failure.
One patient also developed a glioblastoma multiforme at
18 months after the transplantation for mantle cell lym-
phoma but remains alive with no recurrent lymphoma at
32 months after transplantation.
A univariate analysis of prognostic factors identiﬁed his-
tologic diagnosis of blastic mantle cell lymphoma (P = .019)
(Figure 3) and receiving ≥3 prior chemotherapy regimens
(P = .004) (Figure 4) as significant predictors of a worse
EFS. A factor of borderline signiﬁcance was bone marrow
involvement at any time before transplantation (P = .075).
Age (P = .50), sex (P = .41), disease status at transplantation
(P = .33), elevated LDH (P = .57), prior radiotherapy (P = .19),
chemosensitivity (P = .49), TBI regimen (P = .36), and time
from diagnosis to transplantation >1 year (P = .49) did not
have statistically signiﬁcant effects on EFS.
Multivariate analysis identiﬁed ≥3 prior chemotherapies
received as the only characteristic maintaining independent
predictive signiﬁcance. Of those patients who had received 3
or more prior therapies, the 2-year EFS was zero compared
with a 45% 2-year EFS for those patients who had received 2
or fewer therapies (P = .004) (relative risk 5.1, 95% CI 1.6-
15.8). No cases of secondary myelodysplasia or acute myeloge-
nous leukemia have been reported in these patients to date.
DISCUSSION
Mantle cell lymphoma is now recognized as a distinctive
disease entity characterized by generalized lymphadenopathy
and frequent bone marrow, blood, and splenic involvement
[8]. Typical immunohistologic features of mantle cell lym-
phoma are positivity for pan-B-cell antigens such as CD19
and CD20, and HLA-DR antigen. Cells usually have the pan-
T-cell antigen CD5 on the surface and are negative for CD10.
Cells are also usually positive for the CD43 antigen and nega-
tive for the CD23 antigen [5,6]. The characteristic cytogenetic
abnormality is t(11;14)(q13;q32). The molecular counterpart
of the t(11;14) abnormality involves an error in V-D-J joining
during immunoglobulin (Ig) heavy-chain gene rearrangement,
resulting in the movement of a putative cellular oncogene adja-
cent to the bcl-1 (11q13) breakpoint into proximity of the
enhancer region of the Ig heavy-chain gene (14q32) [7,8].
The putative oncogene deregulated by the t(11;14) abnormal-
ity has been named PRAD1 or CCND1 and encodes for
cyclin D1, which is overexpressed in nearly all cases of mantle
cell lymphoma [7,8].
Table 1. Characteristics of Patients at Transplantation*
n 40
Age, y 56 (34-66)
Male 31 (78)
Lactate dehydrogenase above normal 14 (35)
≥3 Prior therapies 5 (13)
Lymphoma mass ≥10 cm 1 (3)
Bone marrow positive 26 (67)
Disease status
Primary induction failure 28 (70)
Relapse sensitive 7 (18)
First complete response 5 (13)
*Data are n, median (range), or n (%).
Figure 1. Overall survival for mantle cell lymphoma patients after autologous transplantation (n = 40).
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Now that this specific clinicopathologic entity has
been recognized, retrospective reclassification of prior
clinical trials and prospective studies of conventional
chemotherapy have been performed. The majority of the
trials evaluating anthracycline-based and non–anthracycline-
based regimens have failed to demonstrate prolonged disease-
free survival in the majority of patients, with the median
time to treatment failure being 12 to 18 months and a
median survival of only 3 to 4 years in most series [12]. The
International Prognostic Index, which was originally
designed for other types of aggressive lymphomas, does
segregate patients with an improved prognosis over others;
however, none of the subgroups appear to have a prolonged
disease-free survival [18]. Other studies have demonstrated
alternative poor-prognosis characteristics such as blastic
histology and p53 mutations [19,20].
Because of the poor outcome of mantle cell–lymphoma
patients treated with standard induction and salvage
chemotherapy, the use of HDC and autoHSCT has become
an option for some patients. Initially, this therapy was used
for patients with relapsed or refractory disease and, more
recently, for patients in first complete remission. Several
studies with a small number of patients receiving trans-
plants after relapse have documented some patients with a
sustained disease-free survival, ranging from 24% to 75%
with varying follow-up [21,22]. Factors that appear to be
predictive of a worse outcome are p53 mutations, blastic
histology, and extensive pretreatment of patients [21,22].
One study by Milpied et al. [23] also demonstrated an
improved outcome in patients who received a TBI-based
regimen over a non–TBI-based regimen.
More recently, because of concern over the results of
transplantation in relapsed patients, patients have been
offered transplantation in first complete remission. The
results of transplantation in this patient population are some-
what controversial. Several small studies done in Europe
have demonstrated a 50% to 80% disease-free survival
with 1 to 3 years of follow-up [24,25]. However, a study
done at the Dana Farber Cancer Center (Boston, MA)
demonstrated that 5 of 8 patients with mantle cell lymphoma
Figure 2. Event-free survival for mantle cell lymphoma patients after autologous transplantation (n = 40).
Figure 3. Event-free survival by histologic subtype.
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who underwent transplantation in ﬁrst CR/PR relapsed with
a median of 2 years of follow-up [26]. It has also been docu-
mented that bone marrow involvement with mantle cell lym-
phoma is less amenable to antibody purging [27].
In a recent study from the M.D. Anderson Cancer Cen-
ter (Houston, TX), 25 previously untreated patients with
mantle cell lymphoma received an intensive induction regi-
men with hyper-CVAD (cyclophosphamide, vincristine, adri-
amycin, and dexamethasone) and high-dose methotrexate/
cytarabine followed by high-dose chemotherapy/radiotherapy
and autoHSCT. For these previously untreated patients, the
overall survival and EFS were reported as 92% and 72%,
respectively, at 3 years of follow-up [28]. These results were
compared with an historical control group of similar mantle
cell lymphoma patients treated with CHOP-like regimens
(CHOP: cyclophosphamide, doxorubicin, vincristine, and
prednisone). However, the historical control group had a
median 3-year EFS of 28% with conventional therapy.
This article evaluates a large number of patients with
mantle cell lymphoma who received HDC and autoHSCT at
various points during their disease course. Our results are
similar to other reports of transplantation in this disease
demonstrating that patients who have relapsed multiple times
and have received many prior therapies do not beneﬁt from
this therapy. In fact, our study found that no patients were
disease free at 2 years after transplantation if they had
received 3 or more prior therapies before undergoing
transplantation. At the present time, the best results appear
to be attained when transplantation is used in less heavily
treated patients, preferably in ﬁrst complete remission. Our
study did not ﬁnd any difference in the outcome by trans-
plantation regimen. However, the numbers of patients
treated with different regimens were small in this study, and
further evaluation of enhanced transplantation regimens,
such as the incorporation of monoclonal antibodies, should
be evaluated further. Because our center is a referral center,
certain selection bias is present in the patients enrolled in
this study. This approach may not be able to be generalized
to a large percentage of patients because many patients with
mantle cell lymphoma are older.
Another alternative in selected young patients may be
the use of a related allogeneic donor. In the small number of
cases reported using an HLA-identical related donor, the
relapse rate is much smaller [29]. However, because of the
other toxicities associated with allogeneic transplantation,
the long-term overall EFS may not be signiﬁcantly different
than that for autologous transplantation. Hopefully, with
future developments in modulating graft-versus-host disease
and the antitumor effect of allogeneic or nonmyeloablative
transplantation, results may improve. However, because
none of the current approaches appear to be satisfactory in
patients with mantle cell lymphoma, enrollment of patients
in clinical trials should be encouraged.
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